229. Autoimmune pulmonary alveolar proteinosis Clinical trials / Disease details

Clinical trials : 44 / Drugs : 22 - (DrugBank : 7) / Drug target genes : 3 - Drug target pathways : 14

6 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03006146 (ClinicalTrials.gov)	July 13, 2017	28/11/2016	Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis	Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis	Autoimmune Pulmonary Alveolar Proteinosis	Drug: Sargramostim	Children's Hospital Medical Center, Cincinnati	Rare Diseases Clinical Research Network;National Center for Advancing Translational Science (NCATS)	Completed	18 Years	80 Years	All	10	Phase 1	United States
2	NCT02835742 (ClinicalTrials.gov)	September 1, 2016	13/7/2016	Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan	Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan	Pulmonary Alveolar Proteinosis, Autoimmune	Drug: Sargramostim;Drug: Placebo	Niigata University Medical & Dental Hospital	NULL	Completed	16 Years	80 Years	All	78	Phase 2	Japan
3	NCT02840708 (ClinicalTrials.gov)	May 2016	13/7/2016	SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study	SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study	Pulmonary Alveolar Proteinosis, Autoimmune	Drug: Sargramostim	Niigata University Medical & Dental Hospital	NULL	Completed	20 Years	80 Years	All	14	Phase 1	Japan
4	NCT00901511 (ClinicalTrials.gov)	July 2009	11/5/2009	Whole Lung Lavage (WLL)/Inhaled Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (PAP)	Whole Lung Lavage Followed by Inhaled Sargramostim in the Treatment of Autoimmune Pulmonary Alveolar Proteinosis	Pulmonary Alveolar Proteinosis	Drug: GM-CSF [Leukine (Sargramostim)];Procedure: WLL	IRCCS Policlinico S. Matteo	Agenzia Italiana del Farmaco	Enrolling by invitation	18 Years	N/A	Both	18	Phase 2/Phase 3	Italy
5	EUCTR2008-007086-23-IT (EUCTR)	12/12/2008	27/01/2009	Whole lung lavage followed by inhaled Sargramostim in the treatment of autoimmune pulmonary alveolar proteinosis. - WLL/inhaled GM-CSF in autoimmune PAP	Whole lung lavage followed by inhaled Sargramostim in the treatment of autoimmune pulmonary alveolar proteinosis. - WLL/inhaled GM-CSF in autoimmune PAP	Autoimmune PAP MedDRA version: 9.1;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis	Trade Name: Leukine INN or Proposed INN: Sargramostim	OSPEDALE POLICLINICO S. MATTEO	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy
6	NCT00030056 (ClinicalTrials.gov)	September 2001	30/1/2002	GM-CSF in Patients With Pulmonary Alveolar Proteinosis	Trial of GM-CSF for Alveolar Proteinosis	Pulmonary Alveolar Proteinosis	Drug: GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim)	The Cleveland Clinic	NULL	Terminated	18 Years	70 Years	Both	48	Phase 2	United States